NASDAQ:FBIO - Fortress Biotech, Inc.
$1.62
 $0.16
+10.96%
4:00PM EDT
2019-04-18
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  FBIO     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 42   203. 85   241. 91  
42 stocks rank:  3. 93 K 1. 44 K 1. 05 K
# analyst opinions:  1. 00   14. 51   13. 97  
mean recommendation:  2. 00   2. 09   2. 01  

quick ratio:  1. 63   5. 27   1. 81  
current ratio:  2. 00   5. 62   2. 25  

target price low:  1. 10   84. 80   115. 21  
target price avg:  1. 10   111. 51   137. 51  
target price high:  1. 10   135. 81   157. 84  
1-yr high:  4. 40   114. 23   138. 78  
last close:  1. 62   87. 66   116. 69  
50-day avg:  1. 91   95. 54   123. 44  
200-day avg:  1. 66   94. 25   121. 11  
1-yr low:  0. 57   72. 78   98. 34  
volume:  19. 23 M 4. 11 M 8. 07 M
50-day avg volume:  773. 03 K 2. 76 M 5. 02 M
200-day avg volume:  484. 38 K 2. 92 M 4. 59 M

1-day return:  10. 96 % -0. 41 % 0. 07 %
this week return:  0. 00 % -5. 74 % -4. 11 %
12-wk return:  52. 83 % 1. 61 % -0. 05 %
52-wk return:  -65. 48 % 3. 12 % 8. 78 %

enterprise value (EV):  113. 59 M 48. 94 B 114. 64 B
market cap:  99. 31 M 43. 07 B 104. 73 B
EBITDA:  -117. 94 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 96   4. 22   12. 73  
enterprise/revenue (EV/R):  4. 23   63. 17   12. 84  
total revenue:  26. 88 M 10. 62 B 38. 47 B
total debt:  79. 50 M 12. 24 B 16. 73 B
debt/equity:  402. 69   46. 71   89. 62  
net income (common):  -73. 01 M 2. 20 B 4. 20 B

shares outstanding:  61. 30 M 571. 70 M 1. 24 B
shares:  35. 92 M 571. 81 M 1. 23 B
shares short:  2. 46 M 10. 17 M 13. 00 M
shares short prior month:  1. 73 M 9. 54 M 17. 33 M
short ratio:  6. 11   5. 41   3. 28  
short % of float:  7. 33 % 5. 45 % 2. 38 %
total cash/share:  1. 36   11. 14   9. 33  
total cash:  83. 11 M 6. 71 B 7. 15 B
free cash flow:  -68. 87 M 3. 58 B 2. 96 B
operating cash flow:  -98. 85 M 4. 15 B 4. 30 B

book value:  0. 03   12. 78   26. 92  
price/book:  50. 63   3. 06   -1. 74  
operating margins:  -446. 38 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  77. 22 % 37. 08 % 55. 70 %

1-yr max volatility:  39. 86 % --- ---
1-yr mean volatility:  -0. 13 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 94   2. 40   4. 10  
forward EPS:  -2. 49   3. 97   7. 13  
P/E:  -0. 84   13. 63   22. 72  
forward P/E:  -0. 65   -15. 95   13. 99  
PE/G:  0. 02   -1. 65   -1. 32  
growth:  -41. 18 % 127. 12 % 29. 61 %
earnings high:  -0. 58   1. 00   1. 66  
earnings avg:  -0. 58   0. 77   1. 53  
earnings low:  -0. 58   0. 50   1. 39  
revenue high:  6. 41 M 2. 68 B 10. 78 B
revenue avg:  6. 41 M 2. 59 B 10. 57 B
revenue low:  6. 41 M 2. 49 B 10. 36 B
return on assets:  -38. 76 % -2. 75 % 4. 55 %
return on equity:  -186. 53 % -18. 45 % 5. 46 %
revenue/share:  0. 62   13. 29   55. 46  

beta (1yr vs S&P500):  1. 35   1. 25   0. 93  
sharpe (1yr):  -0. 28   0. 37   0. 70  

held % insiders:  28. 76 % 6. 39 % 3. 38 %
held % institutions:  12. 22 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : FBIO
.        + 0 =             0 :: INITIAL WEIGHT
.    + 36.14 =         36.14 :: spline projection addition
.    x 1.431 =        51.732 :: industry recommendation factor
.    x 2.068 =       107.006 :: symbol recommendation factor
.    x 1.067 =       114.164 :: EV/R factor
.    x 0.996 =       113.721 :: return on assets factor
.    x 0.981 =         111.6 :: return on equity factor
.    x 2.356 =       262.885 :: current ratio factor
.    x 1.503 =       395.105 :: quick ratio factor
.    x 1.079 =       426.214 :: short ratio factor
.    x 2.666 =      1136.161 :: price-to-book factor
.    x 2.116 =      2403.683 :: debt-to-equity factor
.    x 1.153 =      2771.059 :: 50-day avg > 200-day avg
.    x 2.163 =       5994.64 :: P/E weight
.    x 2.209 =     13241.914 :: PE/G factor
.     x 1.55 =     20527.647 :: beta factor
.    x 0.282 =       5792.76 :: sharpe factor
.    x 0.943 =      5464.567 :: target low factor
.      x 0.9 =      4915.817 :: target mean factor
.    x 0.943 =      4637.307 :: target high factor
.     x 1.31 =      6074.353 :: industry 2-weeks return factor
.    x 0.879 =      5338.411 :: "drift" penalty 3 days ago
.    x 0.934 =      4986.862 :: "drift" penalty 5 days ago
.    x 0.915 =      4560.776 :: overall "drift" factor
.    x 0.601 =      2742.629 :: largest single-day jump factor
.    x 0.064 =       176.262 :: low price factor
.      x 1.0 =       176.233 :: factor hist industry gain for week 16
.   cubeRoot =         5.607 :: reduced to standardize
.    - 28.95 =         0.421 :: add/subtract for performance
.                      0.421 :: FINAL WEIGHT for NASDAQ:FBIO


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org